Literature DB >> 28590248

Volume-outcome relationship with transfemoral transcatheter aortic valve implantation (TAVI): insights from the compulsory German Quality Assurance Registry on Aortic Valve Replacement (AQUA).

Kurt Bestehorn1, Holger Eggebrecht, Eckart Fleck, Maike Bestehorn, Rajendra H Mehta, Karl-Heinz Kuck.   

Abstract

AIMS: Previous studies have shown lower rates of in-hospital complications and mortality for patients undergoing surgical aortic valve replacement (sAVR) in high-volume compared with lower-volume hospitals. It was the aim of our study to analyse whether there is a similar volume-outcome relationship for transcatheter aortic valve implantation (TAVI), which is increasingly used in clinical practice. METHODS AND
RESULTS: We analysed all patients with non-emergent transfemoral (TF) TAVI procedures performed in 2014 in 87 German hospitals. We used the German Aortic Valve score 2.0 to calculate the ratio of observed versus expected (O/E) in-hospital mortality. A total of 9,924 patients (age 81.4±1.1 years, 45.3% male, median log EuroSCORE 18.81%, IQR 4.55) were included. Average observed mortality was 4.3±3.3%, while the expected average mortality was 5.4±1.4% (mean O/E ratio: 0.8). Average in-hospital mortality was 5.6±5.0% (range, 0 to 16.7%) in the lowest volume group of hospitals performing <50 TF-TAVI annually compared to 2.4±1.0% (range, 0.5 to 3.7%) in the highest volume hospitals with ≥200 TF-TAVI procedures per year. There was a continuous, statistically significant association of lower O/E ratios with increasing TF-TAVI volumes (p<0.001), but without a clear-cut threshold. Major complications, neurologic events, and rates of new pacemaker implantation were not different between low- and high-volume hospitals.
CONCLUSIONS: Across the spectrum of hospital volumes from 11 to 415 patients undergoing TF-TAVI per year in Germany, there was a continuous, statistically significant association of lower average observed as well as risk-adjusted in-hospital mortality with increasing TF-TAVI volumes.

Entities:  

Mesh:

Year:  2017        PMID: 28590248     DOI: 10.4244/EIJ-D-17-00062

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

1.  2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011.

Authors:  Gudrun Lamm; Matthias Hammerer; Uta C Hoppe; Martin Andreas; Rudolf Berger; Ronald K Binder; Nikolaos Bonaros; Georg Delle-Karth; Matthias Frick; Michael Grund; Bernhard Metzler; Thomas Neunteufl; Philipp Pichler; Albrecht Schmidt; Wilfried Wisser; Andreas Zierer; Rainald Seitelberger; Michael Grimm; Alexander Geppert
Journal:  Wien Klin Wochenschr       Date:  2021-03-23       Impact factor: 1.704

2.  Insight from a large real-world cohort of patients: does it confirm the results of the randomized trials?

Authors:  Nils Perrin; Stéphane Noble
Journal:  Ann Transl Med       Date:  2017-12

3.  Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes.

Authors:  Sameer A Hirji; Ellen McCarthy; Dae Kim; Siobhan McGurk; Julius Ejiofor; Fernando Ramirez-Del Val; Ahmed A Kolkailah; Bernard Rosner; Douglas Shook; Charles Nyman; Natalia Berry; Piotr Sobieszczyk; Marc Pelletier; Pinak Shah; Patrick O'Gara; Tsuyoshi Kaneko
Journal:  JACC Cardiovasc Interv       Date:  2020-02-10       Impact factor: 11.195

Review 4.  Volume-Outcome Relationship in Surgical and Cardiac Transcatheter Interventions with a Focus on Transcatheter Aortic Valve Implantation.

Authors:  Sarah Mauler-Wittwer; Stephane Noble
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

5.  The Relation between Volume and Outcome of Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Authors:  Jialing He; Zhen Zhang; Han Wang; Lin Cai
Journal:  Cardiovasc Ther       Date:  2020-04-18       Impact factor: 3.023

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.